Jennison Associates LLC bought a new stake in shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 75,000 shares of the company's stock, valued at approximately $1,869,000. Jennison Associates LLC owned about 0.15% of Kestra Medical Technologies as of its most recent filing with the Securities and Exchange Commission.
Separately, Caas Capital Management LP purchased a new stake in shares of Kestra Medical Technologies in the 1st quarter worth $1,470,000.
Analysts Set New Price Targets
A number of research firms have commented on KMTS. Wolfe Research began coverage on Kestra Medical Technologies in a research note on Monday, March 31st. They issued an "outperform" rating and a $29.00 price target for the company. Wells Fargo & Company dropped their target price on Kestra Medical Technologies from $28.00 to $27.00 and set an "overweight" rating on the stock in a report on Thursday, July 17th. Piper Sandler assumed coverage on Kestra Medical Technologies in a report on Monday, March 31st. They issued an "overweight" rating and a $27.00 price objective on the stock. Bank of America began coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They issued a "buy" rating and a $30.00 target price on the stock. Finally, The Goldman Sachs Group reduced their price objective on Kestra Medical Technologies from $24.00 to $23.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 16th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $27.33.
Get Our Latest Report on Kestra Medical Technologies
Kestra Medical Technologies Trading Up 1.2%
KMTS traded up $0.20 on Thursday, hitting $16.92. 141,533 shares of the company were exchanged, compared to its average volume of 283,322. Kestra Medical Technologies, Ltd. has a twelve month low of $13.25 and a twelve month high of $26.15. The company has a debt-to-equity ratio of 0.20, a current ratio of 6.72 and a quick ratio of 6.72. The business has a 50-day moving average price of $18.51.
About Kestra Medical Technologies
(
Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.
Further Reading
Before you consider Kestra Medical Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.
While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
